CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 10 enrolled
Drug / intervention
Pimavanserindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04794413
NCT04794413Early Ph 1Completed
CompareCT.gov

An Open Label, Proof-of-Principle, Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome

Joseph Jankovic·interventional·Posted Mar 12, 2021·Updated Mar 12, 2021

In Brief

A Early Phase 1 clinical trial evaluating Pimavanserin for Tourette Syndrome and Tardive Dyskinesia. Completed, enrolled 10 participants across 1 site.

Detailed Summary

This research study is determining if a drug called Pimavanserin if safe and effective in the treatment of the symptoms of Tourette Syndrome. Pimavanserin is an investigational drug for Tourette Syndrome, which means it has not been approved by the United States Food and Drug Administration (FDA) to treat Tourette Syndrome. Pimavanserin has been approved by the FDA as a treatment for hallucinations in Parkinson's Disease. It is currently marketed under the name NUPLAZID (pimavanserin) capsules by Acadia Pharmaceuticals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTourette Syndrome, Tardive Dyskinesia
CountriesUnited States
CollaboratorsAndrew Billnitzer, MD

Timeline

Early Ph 1CompletedFinished
20192020202120222023202420252026
First PostedMar 12, 2021
Enrollment StartNov 12, 2018
Primary CompletionFeb 28, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.3 years ago

Interventions

Pimavanserindrug

Pimavanserin is a serotonin receptor inverse agonist used in treatment of psychosis in Parkinson's disease.